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TRANSLATIONAL RELEVANCE
Many patients with surgically resected non-small lung cancer will eventually develop tumor recurrence or metastasis. We are not yet able to predict who is at highest risk for recurrent disease. In this study, we evaluated a number of biomarkers identified in our laboratories as particularly important in carcinogenesis and correlated their expression to prognosis of patients with surgically resected tumors to create a risk model for tumor recurrence and survival. With an improved understanding of the mechanisms of early stage disease, our goals are to create a program of personalized chemoprevention and therapy for all patients at risk for lung cancer.
For example, studies like this could help us to improve the adjuvant treatment of patients with cancer, by sparing toxicities of chemotherapy for those with a good prognosis and identifying patients with poor prognosis who may benefit from clinical trials utilizing novel therapeutics. Author Manuscript Published OnlineFirst on December 23, 2013; DOI: 10.1158/1078-0432.CCR- 
Introduction
Lung cancer is the leading cause of cancer-related death for both men and women in the United States. Only a minority of patients are diagnosed with disease amenable to surgical resection. The standard of care following surgical resection for patients with stage II or III tumors is adjuvant chemotherapy with a cisplatin-based doublet, but recurrence is common and there are no clinically useful biomarkers to predict the risk of recurrence. As CT-based screening gains wider acceptance, more patients will be diagnosed with early-stage disease, and effective risk stratification models could be very useful.
Numerous risk models for the development of lung cancer have been developed, incorporating clinical factors with or without serum biomarker assays (1) (2) (3) (4) . Individual biomarkers have been studied, including ERCC1, which predicts for a good prognosis and a lack of benefit to adjuvant chemotherapy (5) , and RRM1, which predicts an improved overall survival when expressed at high levels (6) . No risk prediction models are widely used in clinical practice, however, and a risk model incorporating tissue biomarkers as well as clinical factors could inform clinical decision making.
Our goal with this project was to develop a risk model for the development of recurrence and metastases in patients following lung cancer resection, and to assess the relationships between biomarkers, clinical patient characteristics, and outcome. Immunohistochemistry (IHC) was chosen because it is a readily available assay in diagnostic pathology labs and can be applied to routine formalin-fixed paraffin embedded tissues. We selected biomarkers belonging to a series of important molecular pathways involved in lung carcinogenesis, including many pathways associated with the hallmarks of cancer (7). These markers have been investigated using in vitro and in vivo early carcinogenesis models, and were found to be key to the pathogenesis of NSCLC, both adenocarcinoma and squamous cell carcinoma. The markers chosen relate to cell adhesion and extracellular matrix interactions (CASK, CD51 (8) , EpCAM (9), SPP1 (10)), inflammation (CXCR2 (11)), growth factors and effector pathways (IGF-1R (12) IGFBP3 (13), insulin receptor (14) , pIGF-1R, pEGFR (15, 16) ), growth and metabolism (pAkt (17, 18) , pSrc (19) , pmTor (18), pAMPK (20) , pS6 (17) , SFN (21), UBE2C), and DNA replication and repair (FEN1, MCM2, MCM6, TPX2 (21, 22) ). We then aimed to investigate these biomarkers in early stage lung cancer and to gain a better understanding of the cellular and molecular processes that drive lung carcinogenesis.
Methods

Selection of Biomarkers
Twenty one biomarkers were selected by a team of investigators based on our preclinical work in cell lines as particularly important to lung carcinogenesis. The selected markers were: calcium/calmodulin-dependent serine protein kinase (CASK), CD51 (also known as integrin alpha V), chemokine (C-X-C motif) receptor 2 (CXCR2), epithelial cell adhesion molecule (EpCAM), flap structure specific endonuclease-1 (FEN1), insulin-like growth factor-1 receptor (IGF-1R), insulin-like growth factor binding protein 3 (IGFBP3), insulin receptor, minichromosome maintenance complexes 2 and 6 (MCM2 and MCM6), phospho-Akt, phosphoadenosine monophosphate-activated protein kinase (pAMPK), phospho-epidermal growth factor receptor (pEGFR), pIGF-1R, phospho-mammialian target of rapamycin (pmTOR), pS6, pSrc, stratifen (SFN), secreted phosphoprotein-1 (SPP1), targeting protein for Xklp2 (TPX2), ubiquitinconjugating enzyme E2C (UBE2C). Author Manuscript Published OnlineFirst on December 23, 2013; DOI: 10.1158/1078-0432.CCR- clinical data was obtained from the electronic medical record and follow-up visits and direct contact with patients and/or their families, either by certified letter or telephone. Overall survival (OS) was defined as time from tumor resection to death from any cause; recurrence free survival (RFS) was defined as time from tumor resection to lung cancer recurrence or death.
Identification of Patients and Gathering of Clinical Data
Lung Tumor Specimens
NSCLC specimens from surgical cases were fixed using standard clinic protocols. Author Manuscript Published OnlineFirst on December 23, 2013; DOI: 10.1158/1078-0432.CCR- Summary statistics, including frequency tabulation, means, standard deviations, median, and range, were given to describe subject characteristics and biomarkers. The continuous markers were dichotomized by either 0 vs positive or median when appropriate after examining the martingale residuals. The Kaplan-Meier method was used to construct overall survival (OS) and recurrence-free survival (RFS) curves and log-rank test was used to test the difference in survival by covariates. Univariate and multicovariate Cox model were fitted to estimate the effect of prognostic factors, including age, gender, histology, stage, markers (continuous or dichotomized levels when appropriate) on time to event endpoints, including OS and RFS. All statistical tests were two-sided, and p values of less than 0.05 were considered to be statistically significant.
The predictive accuracy of Cox regression models was quantified by C-index, which provides the area under the receiver operating characteristics curve for censored data (26, 27).
A C-index of 0.5 indicates that outcomes are completely random, whereas a C-index of 1 indicates that the model is a perfect predictor. To protect against overfitting during stepwise regression, we used the bootstrap method for internal validation, which allows for computation of an unbiased estimate of predictive accuracy, C-index. We chose bootstrap method because it has been considered as the most efficient among the internal validation methods, datasplitting, cross-validation and Bootstrap (28, 29). Calibration curves, which plot the average Kaplan-Meier estimate against the corresponding 1-, 3-and 5-year predicted probability of OS or RFS rate (by equally dividing patients into 3 groups according to the predicted probability of surviving), were provided to evaluate the performance of the Cox models. We used 200 bootstrap samples in both bootstrap validation and calibration. All computations were carried out in SAS 9.2 and S-plus 8.0 or R 2.12.2.
Results
Research. In univariate analysis for patients' clinic-pathological characteristics and treatments, age, gender, stage, and adjuvant/neoadjuvant treatment were significantly associated with OS.
Gender, stage, necrosis, inflammation, and adjuvant/neoadjuvant treatment were found to be significantly associated with RFS. Severe inflammation was associated with longer RFS compared to mild inflammation; increased necrosis was associated with shorter RFS. Smoking status was not prognostic in our analysis.
Among the biomarkers examined, we found that the observed five year RFS rate was 50% (95% CI: (44%, 57%)) for patients with positive staining for cytoplastmic pAMPK,; and 33% (95% CI: (25%, 44%)) for those with negative results. For patients whose tumors expressed low levels of CXCR2, five year RFS was 49% (95% CI: (42%, 57%)); for those expressing higher levels, 41% (95% CI: (35%, 49%)). Patients with tumors positive for EpCAM had a trend towards improved five year RFS compared to those who did not: 49% (95% CI: (45%, 56%)) vs 39% (95% CI: (31%, 48%)). The five year OS for patients with positive staining for pAMKP was 64% (95% CI: (59%, 71%)) versus 52% (95% CI: (43%, 62%)) for those patients without pAMPK. Five year OS was 66% (95% CI: (60%, 74%)) and 55% (95% CI: (48%, 63%)) for those with low and high levels of staining for CXCR2, respectively; and 66% (95% CI: (60%, 73%)) and 51% (95% CI: (43%, 61%)) for those with positive and negative staining for EpCAM (Table 2 ). See Figure 2 for Kaplan-Meier curves of RFS and OS by these markers.
Multicovariate Cox Model for Recurrence Free Survival
On multicovariate analysis, age and stage, but not other clinical variables, remained significant predictors of outcome. Controlling for age and stage, the multicovariate Cox model (Table 3) 
Multicovariate Cox Model for Overall Survival
The multicovariate Cox model for OS (Table 4) 
Stage I patients
We further evaluated the prognostic effect of these markers in stage I patients by Figure 3) and fitting the same multicovariate models for Tables 2 and 3) . Adjusted for age, cytoplasmic CXCR2, cytoplasmic pAMPK and cytoplasmic pmTOR remained significant factors in RFS, and cytoplasmic pAMPK, cytoplasmic CXCR2 and nuclear FEN1 remained significant factors in OS. Positive cytoplasmic CXCR2 above the median (HR 1.673, p=0.01) was a significant predictor for shorter RFS, whereas positive cytoplasmic pAMPK (HR 0.581, p=0.009) and positive cytoplasmic pmTOR (HR 0.511, p=0.003) were significantly associated with longer RFS. Positive cytoplasmic pAMPK (HR 0.505, p=0.003) was a significant factor for longer OS, whereas higher cytoplasmic CXCR2 above median (HR 1.954, p=0.004), and higher nuclear FEN1 above median (HR 2.116, p=0.001) were significant predictors for shorter OS.
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Discussion
We sought to investigate the impact of specific biomarkers and their relationship to Author Manuscript Published OnlineFirst on December 23, 2013; DOI: 10.1158/1078-0432.CCR- predict for risk or benefit with certain interventions, including retinoids (30), statins (31) , and celecoxib (32) . The Director's Challenge Consortium, which created a large microarray database of resected adenocarcinoma samples, found that models incorporating both clinical data and gene expression data had an improved predictive accuracy compared to models using either alone. Models with only clinical variables were comparable to models with gene expression data alone and no clinical data (33) , suggesting the importance of combining the two approaches. Our risk model incorporates both biomarkers and clinical factors and includes all histologic subtypes of non-small cell lung cancer.
We utilized immunohistochemistry because it is a widely available and clinically applicable technique which can be applied to FFPE tissues. We studied a number of phospoproteins, which are known to be labile, however, we collected these samples using routine clinical standards (fixation in paraffin in about 30 minutes after tissue was sliced and placement in formalin for less than 24 hours). As these markers were prognostic under these conditions, we believe that they could be useful in routine clinical practice as well.
Several of our markers have previously been described as prognostic. In our study, expression of EpCAM predicted for improved OS and RFS. The literature on this topic is mixed, with studies in some malignancies suggesting worse outcomes with higher expression of EpCAM and in other malignancies finding an association with improved prognosis in cancers of the thyroid, kidney, and oral cavity (34, 35) . FEN1 was found to be predictive of shorter OS in our study. This protein is involved in the replication and repair of DNA and has been associated with high grade tumors and poor prognosis (36) . Another series from our institution confirmed our results by demonstrating that higher expression of FEN1 is a marker of poor prognosis in resected stage I lung cancer (22) . IGF-1R predicted for shorter RFS in our group; this has previously been reported (37).
Our findings regarding pAMPK and pmTOR were intriguing; positivity for either marker was associated with improved RFS and OS. The mTOR signaling pathway is a complex pathway involved in energy sensing and control of cell growth (38) . It has been implicated in carcinogenesis, and mTOR inhibitors are in clinical use for renal cell carcinoma and neuroendocrine tumors (39, 40) . mTOR has been found to be a poor prognostic marker in other malignancies (41, 42) , though other groups have reported that it is a marker of good prognosis in resected NSCLC (43, 44) . Among its other roles, mTOR negatively regulates autophagy (45) , which could explain why we found it to be a marker of good prognosis. Also, activity of mTOR is partially controlled by post-translational mechanisms; therefore, mTOR expression may not correlate with mTOR activity (46). AMPK is a negative regulator of mTOR activity, so it is somewhat surprising that both are found to be markers of good prognosis; however, mTOR is also regulated by many other mechanisms (38) . pAMPK has been reported as a marker of good prognosis elsewhere (20) .
Our results suggest that individual protein IHC is unlikely to be clinically useful, as observed differences in outcome between favorable and unfavorable groups are small. Our study is somewhat limited due to a heterogeneous patient population, with multiple different histologies and with some patients who received adjuvant therapy and others who did not. We are not able to create a predictive model for the benefit of adjuvant chemotherapy based on our data. Though there have been numerous efforts by our group and others to create predictive and prognostic risk models, currently these models are not useful to select patients for therapy after surgical resection of NSCLC.
Lung cancer is a deadly malignancy, and cancer prevention and early detection are important goals. By gaining a better understanding of the biology of lung carcinogenesis, we hope to use this knowledge to accurately assess risk and personalize chemoprevention strategies following lung cancer resection. 
